Rossari BiotechQ2 FY25

Rossari Biotech Q2 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹432.9P/E: 15.7Market Cap: ₹2.4K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3
  • The company expects low to mid double-digit top-line growth, aiming for around 12%-13% revenue growth for the full year FY25 (Page 9, Page 12).
  • Export sales are a key growth driver, having grown 32% in H1 FY25 and currently constituting about 25% of overall sales. Exports are expected to outpace domestic growth further (Page 3, Page 9).
  • Volume growth is expected in the Textile segment domestically (~6%-7% YoY growth) despite pricing pressure (Page 5).
  • Animal Health & Nutrition business anticipates a much stronger second half, with Q3 and Q4 traditionally being strong quarters, aided by new products and infrastructure improvements (Page 6, Page 11).
  • New capacities coming online in the next 3-4 months and ongoing CAPEX projects will enhance production, aiming for asset turns of 3x-4x (Page 11, Page 12).
  • Improvement in margin and utilization expected as new products and capacities scale up (Page 12).

See what Rossari Biotech management said on margin guidance — free account, 30 seconds.

Fundraise plans

  • There is no mention in the transcript of any current or planned fundraising through debt or equity.
  • The company is focusing on internal CAPEX of around Rs. 120-130 crore this year, primarily for capacity expansion and project modifications, funded through existing resources.
  • No indications or discussions about raising fresh capital via equity or debt instruments were noted during the Q2 FY25 earnings call.
  • The management appears confident about meeting growth and margin targets using their operational cash flows and existing funds.
  • Emphasis is on optimizing capacity utilization, new product initiatives, and expanding export markets rather than seeking external funding.

See what Rossari Biotech management said on order book — free account, 30 seconds.

Capex plans

Yes
  • Ongoing CAPEX projects at Unitop and Dahej facilities with about Rs. 60 - Rs. 65 crore already spent.
  • A similar amount expected to be spent over the next 6 months.
  • Projects to be commissioned in Q3, Q4 of the current year and Q1 of next year.
  • Total project budget enhanced by Rs. 18.25 crore, now up to Rs. 146.25 crore due to design modifications.
  • Additional acquisition of 39,101 sqm land adjacent to Dahej facility for future expansion.
  • These investments aimed at serving high-growth segments such as agrochemicals, home & personal care, and specialty chemicals.
  • Expected asset turn of roughly 3x-4x from these investments.
  • Establishment of Rossari Biotech Trading FZE in UAE for export market distribution and sales.
  • Acquisition of 100% equity in Unistar Thai Company Limited, focusing on specialty chemical manufacturing.

Track Rossari Biotech — get its next earnings analysis in your feed

How does Rossari Biotech rank vs peers in Chemicals & Petrochemicals?

Pro feature
ThisRossari Biotech
Rev 3Mar 3

How does Rossari Biotech rank in Chemicals & Petrochemicals?

Compare Rossari Biotech against every Chemicals & Petrochemicals company (Q2 FY25) on revenue, margins and earnings-call signals.

View Chemicals & Petrochemicals leaderboard →

Others in Chemicals & Petrochemicals this season

  • Seya Industries (Q2 FY27)

    Revenue from Operations (Net) for the quarter ended September 30, 2026: ₹0 lakhs (no sales reported). Key results statement takeaways from Seya Industries Ltd's

  • DCM Shriram Fine Chemicals (Q2 FY27)

    9,622.39 lakhs for the quarter ended September 30, 2025, indicating a year-on-year decrease of approximately 7.8%. Key results statement takeaways from DCM Shri

  • Dhariwalcorp (Q2 FY27)

    For the half year ended September 30, 2026, consolidated revenue from operations is ₹23,640.36 lakhs, up from ₹17,767.97 lakhs in the previous comparable…

  • Agastya Energy (Q2 FY27)

    For the quarter ended 30th September 2026, the consolidated revenue from operations was ₹625.15 lakhs, down from ₹4410.2 lakhs in the same quarter last year…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →